Penn Medicine registers PICSTAT pilot testing CD8 PET imaging with Iovance's lifileucel
New early phase 1 trial at Penn will use Zr-89 crefmirlimab berdoxam PET/CT scans to guide lifileucel treatment in advanced melanoma, with Iovance as collaborator.
This week's update centers on a newly registered pilot study exploring whether imaging can sharpen the delivery of an existing tumor-infiltrating lymphocyte therapy.
- A new early phase 1 study, "PICSTAT," sponsored by the Abramson Cancer Center at Penn Medicine with Iovance Biotherapeutics as collaborator, was posted on ClinicalTrials.gov as not yet recruiting. The study is being performed to find out whether Zr-89 crefmirlimab berdoxam "CD8 PET/CT" scans can improve the effectiveness of the tumor-infiltrating lymphocyte (TIL) therapy called lifileucel in treating metastatic melanoma.1 The trial plans to enroll 10 participants in unresectable or metastatic melanoma, with a single-group, treatment-focused design.1 Its primary outcome is the number of viable TILs harvested from resected tumor tissue, measured over 8 to 12 weeks.1 Study start is estimated for October 2026, with primary completion estimated in October 2028.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.